Companies · Pharmaceuticals

Receptor Holdings, Inc.

SEATTLE · Pharmaceuticals

Diligence memoA one-page analyst read on Receptor Holdings, Inc. — recommendation, valuation, rhythm, risks.
$36.2M
Total raised · real
2
Rounds
0.3×
Latest step-up
Top 24%
Sector rank · raised
Series B
Latest stage · inferred · Mon Dec 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Receptor Holdings, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.29× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.6 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Receptor Holdings, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
7.7 yr record
Peak capital year was 2018 with $28.9M across 1 filings.
Market position
ahead of 77% of Pharmaceuticals peers
Capital scale is ahead of 77% of Pharmaceuticals peers; modeled value is above 62% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2018: $28.9M across 1 filings.
  • Largest single filing was $28.9M on 2018-10-15.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Receptor Holdings, Inc. is one of 1613 Pharmaceuticals companies tracked from SEATTLE. By capital raised it ranks in the upper tier (ahead of 77% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
45
Investors (latest)
2018
Year incorporated
2021-12-06
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2018-10-15 Raised $29M (real) Modeled valuation $982M (est)$29M$982MSeries B2018Series B · 2021-12-06 Raised $7.3M (real) Modeled valuation $141M (est)$7.3M$141MSeries B2021+$7.3MCumulative $36M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$28.9M · 2018
Series B extension$7.3M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$141.0M
Base estimate est.
$15.3M
Conservative case
$412.7M
Upside case
$40.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series B · modeled $981.9M · 2018-10-152018Series B · modeled $141.0M · 2021-12-062021
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
57%
Survival probability
38% low · 70% high
1.49×/yr
Annual markup
1.80×/yr upside case
4.6 yr
Elapsed time used
4.6 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
38 mo
Avg between rounds
$11.5M/yr
Capital velocity
7.7 yr
On record since
2018
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.5× above median
This company$36.2M
Sector median$8.1M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.4× of median
This company$7.3M
Sector median$18.0M
Modeled value — vs sector median (estimate, all stages) 1.9× above median
This company$141.0M
Sector median$76.1M

Raised more than 77% of sector peers (real $). Modeled value above 62% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #51 of 61.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Evolus, Inc. · Series B Raised $40.5M · modeled $1.4B (est)HOOKIPA Pharma Inc. · Series B Raised $37.4M · modeled $1.3B (est)ESSA Pharma Inc. · Series B Raised $56.0M · modeled $1.2B (est)Pieris Pharmaceuticals, Inc. · Series B Raised $102.1M · modeled $1.1B (est)Amylyx Pharmaceuticals, Inc. · Series B Raised $65.1M · modeled $1.0B (est)PassPort Technologies, Inc. · Series B Raised $30.0M · modeled $1.0B (est)Savara Inc · Series B Raised $30.9M · modeled $910.6M (est)InCarda Therapeutics, Inc. · Series B Raised $66.3M · modeled $857.5M (est)Aceto Management, L.L.C. · Series B Raised $23.6M · modeled $803.2M (est)GPI Finco (Canada) Inc. · Series B Raised $22.9M · modeled $778.0M (est)Phosplatin Therapeutics LLC · Series B Raised $72.3M · modeled $722.8M (est)Lannett Co Inc · Series B Raised $28.0M · modeled $691.3M (est)Receptor Holdings, Inc. (this company) Raised $36.2M · modeled $141.0M (est)Receptor Holdings, Inc.
CompanyStageRaised · realValue · estvs peer med.
Evolus, Inc.Series B$40.5M$1.4B2.74×
HOOKIPA Pharma Inc.Series B$37.4M$1.3B2.57×
ESSA Pharma Inc.Series B$56.0M$1.2B2.47×
Pieris Pharmaceuticals, Inc.Series B$102.1M$1.1B2.20×
Amylyx Pharmaceuticals, Inc.Series B$65.1M$1.0B2.06×
PassPort Technologies, Inc.Series B$30.0M$1.0B2.06×
Savara IncSeries B$30.9M$910.6M1.84×
InCarda Therapeutics, Inc.Series B$66.3M$857.5M1.73×
Aceto Management, L.L.C.Series B$23.6M$803.2M1.62×
GPI Finco (Canada) Inc.Series B$22.9M$778.0M1.57×
Phosplatin Therapeutics LLCSeries B$72.3M$722.8M1.46×
Lannett Co IncSeries B$28.0M$691.3M1.40×
Receptor Holdings, Inc. this companySeries B$36.2M$141.0M0.29×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$28.9M2018-10-15$160.4M$981.9M90%
Series B$7.3M2021-12-06$40.6M$141.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$28.9M2018-10-15
    • First recorded raise — entered as Series B.
    • 75 investors on this round.
  2. Series B$7.3M2021-12-06
    • Raised again after 38 mo — slower than the ~13 mo sector norm.
    • Round 4.0× smaller than the prior — bridge or down round.
    • 45 investors on this round.
Intelligence
2025 ~Q1
Modeled next raise · ~38mo cadence
$7.3M
Modeled next size est.range $7.3M$11.7M
0.3×
Last step-up
$11.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Gregory Mayes4 other2021-12
Arthur Rubinfeld3 other2018-10
Mark Theeuwes2 other2021-12
Warren Lammert2 other2021-12
Gregory Wesner1 other2018-10
Traci Carman1 other2018-10
Andrea Leone-Bay2021-12
Greg Wesner2021-12
Jim Weissman2021-12
Orrin Devinsky, MD, PhD2021-12
Stephen Hoffman, MD, PhD2021-12
Registry & provenance

Receptor Holdings, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1757296
SEC CIK
2018
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Engage Therapeutics, Inc.PharmaceuticalsSeries B$30.6M$238.0Mnetwork3 shared operators · same sector · same stage
Cerebral Therapeutics, Inc.PharmaceuticalsSeries B$31.0M$680.1Mnetwork1 shared operator · same sector · same stage
Reunion Neuroscience, Inc.PharmaceuticalsSeries D+$119.8M$1.5Bnetwork2 shared operators · same sector
Receptor Life Sciences, Inc.OtherSeries A$7.6M$114.6Mnetwork3 shared operators
Triton Therapeutics, Inc.PharmaceuticalsSeries B$36.4M$152.5Msame sector · same stage
Rx Redefined Inc.PharmaceuticalsSeries B$35.7M$126.1Msame sector · same stage
DisperSol Technologies, LLCPharmaceuticalsSeries B$37.0M$143.8Msame sector · same stage
Verismo Therapeutics, Inc.PharmaceuticalsSeries B$35.2M$197.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Receptor Life Sciences, Inc.OtherSeries A$114.6M86%
Cellectar Biosciences, Inc.PharmaceuticalsSeries B$236.5M83%
Hapten Sciences, Inc.PharmaceuticalsSeed$64.2M82%
Navitor Pharmaceuticals, Inc.PharmaceuticalsSeries B$686.4M82%
Sator Holdings LLCPharmaceuticalsPre-Seed$11.8M82%
MedAvail Holdings, Inc.PharmaceuticalsSeries B$679.3M82%
Acendrx, Inc.PharmaceuticalsSeed$95.1M82%
Shuttle Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$7.1M81%
Frequently asked
How much funding has Receptor Holdings, Inc. raised?
Receptor Holdings, Inc. has raised approximately $36.2M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Receptor Holdings, Inc.'s estimated valuation?
Provath's modeled valuation for Receptor Holdings, Inc. is approximately $141.0M (modeled range $15.3M–$412.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Receptor Holdings, Inc. at?
Receptor Holdings, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Mon Dec 06.
What does Receptor Holdings, Inc. do and where is it based?
Receptor Holdings, Inc. operates in the Pharmaceuticals sector, based in SEATTLE.
Explore related

See where Receptor Holdings, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Receptor Holdings, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.